The World Health Organization (WHO) estimates that if current trends persist, antibiotic resistance could cause 10 million deaths annually by 2050. The pharmaceutical industry is the primary source of antibiotic innovation; therefore, it must lead the way in combating resistance.
Urgency of Antibiotic Resistance
The escalating threat of antibiotic resistance is an incoming global crisis projected to affect international health and the economy. Multidrug-resistant (MDR) infections, such as methicillin-resistant Staphylococcus aureus and carbapenem-resistant Enterobacteriaceae (CRE), are becoming increasingly prevalent, making once-reliable antibiotics ineffective. These pathogens are not only associated with increased morbidity and mortality but also create a substantial economic burden on healthcare systems worldwide. A study from Oxford University demonstrated that in 2019, 1.27 million deaths were directly attributable to antibiotic resistance, with another 4.95 million deaths associated with it. The World Bank’s projection of a potential $3.4 trillion loss in GDP by 2030 shows the urgency of this crisis.
The erosion of existing antibiotic efficacy due to resistance presents a challenge — an urgent public health crisis and a potential market opportunity. While the demand for novel antibiotics is undeniable, the industry still struggles with the harsh realities of antibiotic drug development. This costly, high-risk development pipeline has high attrition rates and uncertain market returns.
R&D for Novel Antimicrobial Compounds
Developing novel antimicrobial compounds is crucial in combating resistance. The antibiotic pipeline has been dwindling in recent years, with a decrease in the development of novel antibiotics, particularly those targeting Gram-negative bacteria, which are notoriously difficult to treat due to their complex cell wall structures. This decline in R&D is attributed to scientific challenges associated with identifying new antibiotic targets and the relatively low return on investment compared to other therapeutic areas like oncology or rare diseases.
Pharmaceutical companies are, therefore, exploring innovative approaches. This includes targeting novel bacterial pathways, such as quorum sensing, which bacteria use to communicate and coordinate group behaviours like biofilm formation, and efflux pumps, which actively expel antibiotics from bacterial cells. Additionally, the development of alternative antimicrobial drugs, such as antibody-drug conjugates, which combine the specificity of antibodies with the potency of cytotoxic drugs, and bacteriophage therapy, which utilizes viruses that infect and kill bacteria, offer promising avenues for overcoming resistance.
For instance, GSK and the Biomedical Advanced Research and Development Authority have collaborated to develop new antibiotics targeting Gram-negative pathogens. Their joint efforts have led to the development of gepotidacin, a novel first-in-class antibiotic that inhibits the bacterial enzymes topoisomerase II and DNA gyrase, which are essential for DNA replication and repair. Gepotidacin has shown promising results in clinical trials for uncomplicated urinary tract infections and gonorrhea, demonstrating its potential to address the growing threat of MDR Gram-negative infections.
Another promising approach to antibiotic development is the use of antibiotic adjuvants, which are substances that enhance the activity of existing antibiotics. These adjuvants can work by inhibiting resistance mechanisms, enhancing antibiotic uptake, or potentiating the antibiotic’s activity against the target bacteria. For example, beta-lactamase inhibitors, such as clavulanic acid and sulbactam, are commonly used with beta-lactam antibiotics to overcome resistance mediated by beta-lactamase enzymes that break down beta-lactam antibiotics.
Data science and artificial intelligence (AI) convergence is making antibiotic R&D more streamlined. Machine learning algorithms, capable of parsing vast datasets of bacterial genomes and protein structures, are expediting the discovery of novel antibiotics. For instance, MIT researchers utilized machine learning to identify a novel antibiotic, halicin, that effectively eradicated a wide range of drug-resistant bacteria in preclinical models. This study highlights AI’s potential to discover novel antibiotics with unique mechanisms of action that can overcome existing resistance mechanisms. Furthermore, AI-powered platforms are being employed to predict antibiotic susceptibility and resistance profiles, enabling the development of personalized treatment strategies that optimize antibiotic use and minimize the risk of resistance emergence.
Antibiotic Stewardship
While developing new antibiotics is essential, ensuring appropriate access and responsible use of existing antibiotics is equally crucial. Inappropriate antibiotic use, such as suboptimal doses, can accelerate the emergence and spread of resistance. Therefore, pharmaceutical companies are responsible for promoting proper antibiotic use through educational initiatives and support for antibiotic stewardship programs (ASP).
ASP are comprehensive programs that optimize antibiotic prescribing by ensuring the correct antibiotic is used for the right patient at the right time and dose. This involves implementing evidence-based guidelines, such as those developed by the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). These ASP work by monitoring antibiotic use patterns through electronic health records and surveillance systems, while providing feedback to clinicians and pharmacists to improve their prescribing practices. Studies have shown that ASP can significantly reduce antibiotic consumption, and improve patient outcomes without compromising clinical efficacy.
Pfizer, for example, has established a comprehensive ASP that encompasses a global surveillance network to track antibiotic resistance patterns and advocacy efforts to raise awareness about the importance of responsible antibiotic use. The company also provides grants to support research on antibiotic resistance and stewardship, and it has partnered with organizations like the WHO and the CDC to develop and implement global initiatives to address this critical issue.
Collaborative Global Health Efforts
Addressing antibiotic resistance requires a collaborative effort from all stakeholders, including pharmaceutical companies, governments, healthcare providers, academia, and patient advocacy groups. Public-private partnerships (PPP) can be crucial in pooling resources and knowledge to accelerate research and promote responsible use.
The Innovative Medicines Initiative (IMI), a PPP between the European Union and the European pharmaceutical industry, has launched several initiatives to combat antibiotic resistance. These include the New Drugs for Bad Bugs (ND4BB) program, which aims to accelerate the development of new antibiotics for Gram-negative bacteria, and the COMBACTE project, which focuses on developing new diagnostics and treatments for antibiotic-resistant infections. The ND4BB program, for instance, has supported the development of several promising new antibiotics, such as cefiderocol, a novel siderophore cephalosporin that has shown activity against CRE.
In addition to IMI, other notable PPP include the AMR Action Fund, a global initiative that invests in small biotech companies developing innovative antibiotics, and the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator, an international non-profit partnership that supports the early development of new antibiotics, vaccines, and diagnostics.
Financial Incentives and Alternative Business Models
Given the inherent challenges associated with antibiotic R&D, traditional market-driven models still need to be revised to incentivize innovation. The societal value of antibiotics, crucial for public health, far outweighs their commercial value. This “market failure” stems from several factors, including the relatively short antibiotic treatment duration and the pressure to maintain affordability for broad access. This misalignment of incentives disincentivizes substantial investment in antibiotic R&D.
To address this market failure, governments and international organizations are exploring innovative financial mechanisms to stimulate antibiotic innovation. Push incentives, such as grants, tax breaks, and R&D subsidies, can help with the high costs of antibiotic development. For instance, the U.S. Generating Antibiotic Incentives Now (GAIN) Act, passed in 2012, offers incentives like extended market exclusivity and faster regulatory review for qualified infectious disease products. In Europe, the ND4BB program funds collaborative research projects to develop new antibiotics for Gram-negative bacteria.
Pull incentives, designed to reward successful antibiotic development, are also gaining traction. These include market entry rewards, which offer substantial lump sum payments to companies that successfully bring new antibiotics to market, and transferable exclusivity vouchers, which extend the market exclusivity of a different drug in the company’s portfolio. Such incentives aim to bridge the gap between antibiotics’ societal and commercial value, making them more financially attractive for investment.
One example of a pull incentive is the DISARM Act (Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act) in the United States, which proposes to establish a model where pharmaceutical companies would receive a fixed annual payment for access to their novel antibiotics, regardless of sales volume. This model aims to provide antibiotic developers with a more predictable and sustainable revenue stream, encouraging investment in this critical area.
In addition to these government-led initiatives, alternative business models are being explored to incentivize antibiotic innovation. Subscription-based models, where governments or healthcare systems pay a fixed annual fee for access to a portfolio of antibiotics, are gaining traction. This approach provides a more predictable revenue stream for pharmaceutical companies, reducing the risk associated with antibiotic development. Furthermore, delinked models, which decouple the price of antibiotics from sales volume, are being considered. These models reward companies for the value their antibiotics bring to society rather than the number of doses sold, incentivizing the development of new antibiotics while discouraging overuse.
Implementing these innovative financial mechanisms and alternative business models is crucial for fostering a sustainable ecosystem for antibiotic innovation. By aligning economic incentives with public health goals, we can ensure that pharmaceutical companies have the resources and motivation to develop the new antibiotics we desperately need to combat the growing threat of antibiotic resistance.
Stay informed by signing up for our newsletter, where you’ll gain early access to the latest insights, trends, and breakthroughs in drug discovery, powered by cutting-edge data and analysis from industry-leading experts.